Zogenix Reports First Quarter 2013 Financial Results
May 09, 2013 16:01 ET
|
Zogenix
Provides Update on Zohydro ER
Conference Call and Webcast Today, May 9, at 4:30 p.m. ET
SUMAVEL® DosePro® (sumatriptan injection) First Quarter 2013 Highlights
Net product...
Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results
May 03, 2013 07:30 ET
|
Zogenix
SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain,...
Zogenix Reports Positive Top-Line Results From Extended Relday(TM) Phase 1 Clinical Trial
May 02, 2013 07:30 ET
|
Zogenix
SAN DIEGO, May 2, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain,...
Zogenix and Battelle Extend DosePro Co-Marketing Partnership
March 27, 2013 08:00 ET
|
Zogenix
SAN DIEGO and COLUMBUS, Ohio, March 27, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous...
Zogenix Reports Fourth Quarter and Full Year 2012 Financial Results
March 15, 2013 07:30 ET
|
Zogenix
SUMAVEL® DosePro® (sumatriptan injection) Highlights
2012 net product revenue of $35.9 million, up 18% over 2011
Fourth quarter net product revenue of $9.5 million, up 12% over...
Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2012 Financial Results
March 07, 2013 07:30 ET
|
Zogenix
SAN DIEGO, March 7, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Provides Update on Zohydro(TM) ER Regulatory Review
February 26, 2013 20:05 ET
|
Zogenix
SAN DIEGO, Feb. 26, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Announces Preliminary Fourth Quarter 2012 Gross Product Sales
January 07, 2013 07:30 ET
|
Zogenix
SAN DIEGO, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Reports Positive Results From Relday(TM) Phase 1 Clinical Trial
January 03, 2013 07:30 ET
|
Zogenix
SAN DIEGO, Jan. 3, 2013 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain,...
Zogenix Provides Update on FDA Advisory Committee Meeting for Zohydro(TM) ER for Management of Chronic Pain
December 07, 2012 17:45 ET
|
Zogenix
SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...